Company intelligence / Profile preview

Sinovant Sciences

Shanghai, Shanghai, Chinaprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Sinovant has advanced several innovative medicines addressing major public health needs in China, including liver cancer and drug-resistant infections. Its pipeline includes small molecule drugs in Phase 2 trials for GI and oncology indications, as well as earlier-stage dermatology programs. The company outlicensed its antibiotic lefamulin to Sumitomo after successful Chinese trials showing non-inferiority to moxifloxacin for pneumonia.[7] It also co-founded Cytovant to develop cell therapies targeting Asian patient populations.[8]

Therapeutic areas: OncologyImmunologyDermatologyUrologyGastroenterologyInfectious Diseases
Modalities: Small molecules[3]Cellular therapies (via subsidiary Cytovant)[8]
Industry: Biotech

Drug pipeline

1 asset

SNV-002

Preclinical

Partnerships

Medigene AG – multi-program license/collaboration agreement for T-cell immunotherapies via Cytovant subsidiary [8].Renexxion – naronapride development rights for China [6].Sumitomo Dainippon Pharma – acquired Chinese rights to lefamulin antibiotic from Sinovant [7].

Beyond the preview

Go deeper on Sinovant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinovant Sciences.

Explore the full profile